Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1 Multiple Myeloma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumors 1

Interventions

Paclitaxel 68 Carboplatin 64 pembrolizumab 32 Cyclophosphamide 32 Bevacizumab 27 liposomal doxorubicin 24 Cisplatin 24 Topotecan 21 Gemcitabine 21 olaparib 18 fludarabine 17 Taxes 16 Docetaxel 15 Nivolumab 14 Doxorubicin 14 niraparib 13 veliparib 12 Albumin-Bound Paclitaxel 11 aldesleukin 9 Filgrastim 9 fludarabine phosphate 8 durvalumab 8 Oxaliplatin 8 Fluorouracil 8 Drug Therapy 8 sargramostim 7 Peripheral Blood Stem Cell Transplantation 7 Magnetic Resonance Spectroscopy 7 Leucovorin 7 talazoparib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Ovarian Neoplasms × Maximum Tolerated Dose × Clear all

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡